Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T20:48:54.673Z.
Calculation as of: 2026-10-06T20:48:54.673Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc3fa1fa429e6ac4f0d7012b2af5cf8e78abb5153a19c38995711b2f102458f4
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 4.41 | 4.41 | 4.41 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute